Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who purchased its securities during the specified class period, alleging that the company made false or misleading statements regarding its business and operations [1][3]. Company Overview - Telix Pharmaceuticals Ltd. is a biopharmaceutical company based in Melbourne, Australia, focusing on the development of radiopharmaceuticals for cancer treatment [3]. Allegations - The lawsuit claims that Telix overstated progress on its prostate cancer therapeutic candidates [3]. - It is alleged that the quality and performance of the company's supply chain and partners were exaggerated [3]. - As a result of these misrepresentations, statements regarding the company's business, operations, and prospects were deemed false or misleading [3]. Investor Information - Investors who purchased Telix securities during the class period have until January 9, 2026, to seek appointment as lead plaintiff representatives [2].

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: ht ...

Philadelphia, Pennsylvania--(Newsfile Corp. - January 6, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").Investor Deadline: Investors who purchased Telix securities during the Class Period may, no later than January 9, 2026, seek to be ...

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited for allegedly making false and misleading statements regarding its prostate cancer therapeutic candidates and supply chain quality, leading to investor losses during the specified class period [3][7]. Allegation Details - The lawsuit claims that defendants materially overstated the progress of Telix's prostate cancer therapeutic candidates [3]. - It is alleged that the quality of Telix's supply chain and partners was also overstated [3]. - As a result, statements made by the defendants about Telix's business, operations, and prospects were materially false and misleading, lacking a reasonable basis [3]. Next Steps - Investors who purchased or acquired Telix shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 9, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across state and federal courts [5]. - The firm has offices in New York, California, and South Carolina [5].

Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and supply chain reliability, which resulted in significant investor losses [1][2][3]. Regulatory Setbacks - Telix Pharmaceuticals faced regulatory challenges, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, leading to a 21% decline in stock value following the final news [2][7]. - The SEC is investigating the company's disclosures related to the development of its prostate cancer therapeutic candidates, TLX591 and TLX592, suggesting misleading statements about their advancement [7]. Allegations of Misrepresentation - The lawsuit claims that Telix and its executives overstated the developmental progress of their therapeutic candidates and misrepresented the reliability of their third-party supply chain and manufacturing partners [2][3]. - The complaint alleges that the SEC questioned the development disclosures, while the FDA rejected a Biologics License Application (BLA) due to deficiencies in Chemistry, Manufacturing, and Controls (CMC) [3][7]. Investor Impact - The cumulative effect of the regulatory disclosures allegedly caused significant financial damage to investors who purchased Telix ADSs during the Class Period from February 21, 2025, to August 28, 2025 [7]. - The firm Hagens Berman is encouraging affected investors to contact them to discuss their rights and potential recovery options [4][5].

Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. on behalf of investors who purchased its securities during the specified Class Period, alleging misleading statements regarding the company's business and operations [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who bought Telix securities from February 21, 2025, to August 28, 2025 [1][2]. - Investors have until January 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against Telix - Defendants are accused of making false or misleading statements and failing to disclose that Telix overstated its progress with prostate cancer therapeutic candidates [3]. - The company allegedly exaggerated the quality of its supply chain and partners, leading to misleading statements about its business and prospects [3]. - The complaint claims that when the true state of Telix's business was revealed, investors experienced significant financial losses [3].

Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and supply chain reliability, leading to significant investor losses [1][2][3]. Regulatory Issues - The lawsuit follows regulatory setbacks, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in Telix's stock price [2][7]. - The SEC is investigating Telix for potentially misleading disclosures about the development of its prostate cancer therapeutic candidates [7]. Allegations of Misrepresentation - The complaint claims that Telix and its executives overstated the progress of their therapeutic candidates and misrepresented the reliability of their third-party supply chain and manufacturing partners [2][3]. - It alleges a dual regulatory failure, with the SEC questioning development disclosures and the FDA rejecting a Biologics License Application (BLA) due to deficiencies in Chemistry, Manufacturing, and Controls (CMC) [3][7]. Investor Impact - The cumulative effect of the regulatory disclosures led to substantial losses for investors who purchased Telix ADSs during the Class Period from February 21, 2025, to August 28, 2025 [7]. - The firm Hagens Berman is urging affected investors to contact them to discuss their rights and potential recovery [4][5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements regarding the company's prostate cancer therapeutic candidates and supply chain quality, which have resulted in significant stock price declines [2][4][5][6]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Telix between February 21, 2025, and August 28, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Telix, with a deadline of January 9, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [7]. Group 2: Allegations Against Telix - The complaint alleges that Telix and its executives violated federal securities laws by making false and misleading statements about the progress of their prostate cancer therapeutic candidates and the quality of their supply chain [4]. - Specific allegations include that Telix materially overstated its progress and the quality of its partnerships, leading to misleading statements about its business and operations [4]. - Following the announcement of a subpoena from the U.S. Securities and Exchange Commission, Telix's stock price fell over 13% in two trading sessions [5]. Group 3: Regulatory Challenges - On August 28, 2025, Telix disclosed receiving a Complete Response Letter from the FDA regarding its product TLX250-CDx, citing deficiencies in the Chemistry, Manufacturing, and Controls package [6]. - This disclosure led to a further decline of over 21% in Telix's stock price over two trading sessions [6].

Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a securities class action lawsuit due to alleged misstatements regarding the progress of its prostate cancer drug TLX591 and deficiencies in its third-party manufacturing processes, leading to significant investor losses [2][3]. Regulatory Issues - The lawsuit follows regulatory setbacks, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in stock value [2][7]. - The SEC is investigating the company's disclosures related to the development of its therapeutic candidates, suggesting misleading statements about their advancement [7]. - The FDA rejected the Zircaix application, citing severe deficiencies in Chemistry, Manufacturing, and Controls (CMC), and issued Form 483 notices to two third-party supply chain partners, revealing foundational weaknesses that were allegedly concealed [7]. Allegations of Misstatements - The complaint alleges that Telix and its executives materially overstated the developmental progress of its therapeutic candidates and misrepresented the reliability and regulatory compliance of its third-party supply chain and manufacturing partners [2][3]. - Documented failures in regulatory compliance were allegedly concealed, making the company's claims of "great progress" and "truly global manufacturing capability" materially false [3]. Investor Impact - The cumulative effect of the regulatory disclosures led to a sharp decline in Telix ADSs, with a notable 21% drop following the final regulatory news, resulting in significant damages for investors who purchased TLX ADSs during the Class Period from February 21, 2025, to August 28, 2025 [7].

Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and supply chain reliability, leading to significant investor losses [1][2][3]. Regulatory Issues - The lawsuit follows regulatory setbacks, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in Telix's stock price [2][7]. - The SEC is investigating Telix's disclosures related to the development of its prostate cancer therapeutic candidates, suggesting misleading statements about their advancement [7]. - The FDA rejected Telix's Zircaix application, citing severe deficiencies in Chemistry, Manufacturing, and Controls (CMC), and issued Form 483 notices to two third-party supply chain partners, revealing foundational weaknesses that were allegedly concealed [7]. Allegations of Misrepresentation - The complaint alleges that Telix and its executives materially overstated the developmental progress of its therapeutic candidates and misrepresented the reliability and regulatory compliance of its third-party supply chain and manufacturing partners [2][3]. - The complaint claims that these documented failures were material and concealed, making the company's claims of "great progress" and "truly global manufacturing capability" materially false [3]. Investor Impact - The cumulative effect of the regulatory disclosures allegedly caused Telix ADSs to fall sharply, leading to damages for investors who purchased TLX ADSs during the Class Period from February 21, 2025, to August 28, 2025 [7]. - The firm Hagens Berman is urging Telix investors who suffered substantial losses to contact them to discuss their rights [4][5].